26 May 2020
Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
Tag: voluntary licence
22 May 2020
Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
20 May 2020
The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.
19 May 2020
Letter
Include Malaysia And Other Middle-Income Countries in All Licensing Agreements For Covid-19 Diagnostics, Treatments, And Vaccines — MHC & DNDi
Gilead excluded Malaysia, among other middle-income countries, from distribution of Remdesivir to 127 nations under voluntary licensing.
4 December 2019
Gilead announced in August 2017 the expansion of its sofosbuvir voluntary licensing programme to Malaysia.
20 September 2019
Voluntary licences can lead to an extra 54 to 69 people annually receiving Hepatitis C treatment per 1,000 individuals diagnosed.